Clinical trials
MRD clinical trials
Below are recruiting mrd clinical trials, each written for real people, not researchers. We’re tracking 110 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06511882RecruitingPhase 2
Stopping AML treatment after reaching remission with no detectable disease
This trial tests whether it is safe to stop taking a type of chemotherapy (azacitidine or decitabine) combined with venetoclax if you have acute myeloid leukemia (AML) and have achieved a remission with no trace of leukemia cells. If you have been on this treatment for less than a year and are not eligible for a stem cell transplant, you may be able to stop therapy and be monitored closely.
Tampa, FloridaAges 18 years+ - NCT06517212RecruitingPhase 2
Tirzepatide for weight loss in MRD-positive early breast cancer
This study tests whether the weight-loss drug tirzepatide (Mounjaro) can help prevent breast cancer from coming back in people who are overweight and have a sign of leftover cancer cells in their blood (called MRD-positive). You must have already finished at least one year of hormone therapy for early-stage breast cancer.
Dallas, TexasAges 18 years+ - NCT06595966Recruiting
Blood test study for early detection of breast cancer return
This study looks for tiny bits of cancer DNA in your blood after breast cancer surgery. A blood test called NGS may help doctors find early signs of cancer coming back, and you would give samples and have checkups for 3 years.
Hangzhou, ZhejiangAges 18 years+ - NCT06605404Recruiting
Pan-tumor study of a blood test after cancer surgery
This study is testing a new blood test that looks for leftover cancer cells after surgery. It is for people with different types of solid tumors who are planning to have surgery to cure their cancer. The goal is to see if the test can help guide future treatment decisions.
San Diego, CaliforniaAges 18 years+ - NCT06606028Recruiting
Blood test for leftover cancer DNA after head and neck cancer treatment
This study uses a simple blood test to look for leftover cancer DNA after treatment for head and neck squamous cell carcinoma. The goal is to see if the test can find very small amounts of cancer early, which might help doctors make better decisions about follow-up care.
San Francisco, CaliforniaAges 18 years+ - NCT06608732RecruitingPhase 2
CAR-T therapy plus stem cell transplant for B-cell ALL with MRD
This trial tests a combination of a CAR-T cell therapy (Inaticabtagene Autoleucel) followed by your own stem cells being transplanted back into you. It is for teenagers and adults who have B-cell acute lymphoblastic leukemia (ALL) that is in first complete remission but still has tiny amounts of cancer cells (called MRD) that can be detected by sensitive tests.
Tianjin, Tianjin MunicipalityAges 16–70 - NCT06697483Recruiting
Personalized maintenance therapy for multiple myeloma after stem cell transplant
This trial tests a personalized approach to maintenance therapy for people with multiple myeloma who have already had a stem cell transplant. Your treatment plan may be adjusted based on how well your cancer responds and on certain risk factors, with the goal of keeping you in remission longer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06718244RecruitingPhase 2
CNCT19 for B-ALL with minimal remaining cancer after first remission
This trial tests a CAR-T cell therapy (CNCT19) for people with B-cell acute lymphoblastic leukemia (B-ALL) who still have a tiny amount of cancer cells after standard treatment. The goal is to see if this therapy can clear those remaining cancer cells.
Shanghai, Shanghai MunicipalityAges 16–70 - NCT06752785RecruitingPhase 1
CAR-T cell therapy for children with ALL and minimal residual disease
This trial tests a new treatment using the patient's own immune cells, modified to find and attack leukemia cells that remain after initial chemotherapy. It's for children with B-cell acute lymphoblastic leukemia who still have tiny amounts of cancer cells detectable after standard treatment.
Guangzhou, GuangdongAges 1–18 - NCT06878131Recruiting
Precision-MRD: Targeted therapy study for colorectal cancer with MRD
This study looks at how well targeted therapies work for people with colorectal cancer who have minimal residual disease (MRD, tiny amounts of cancer left after treatment) detected by a blood test. It is for people who have a specific genetic change (biomarker) in their tumor and have not been treated with the targeted therapy for that biomarker before.
Houston, TexasAges 18 years+ - NCT06885476Recruiting
NK cell infusion for AML patients with minimal cancer left
This trial tests if giving special immune cells from a donor can clear leftover leukemia cells in patients who are in remission but still have traces of cancer after chemotherapy.
Bologna, BOAges 18 years+ - NCT06893133Recruiting
DNA testing after gastric cancer surgery
This study checks if a blood test can find leftover cancer DNA after stomach cancer surgery. It helps doctors know if more treatment is needed.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06910124RecruitingPhase 2
Testing linvoseltamab with lenalidomide for multiple myeloma
This trial tests adding a new drug, linvoseltamab, to the standard maintenance therapy lenalidomide for people with newly diagnosed multiple myeloma. The goal is to see if it can deepen responses or turn a relapse back to a negative minimal residual disease (MRD) state, where no cancer cells are detectable.
Miami, FloridaAges Any age - NCT06951646RecruitingPhase 2
Personalized treatment for advanced lung cancer with long response to first-line therapy
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
ChangshaAges 18–75 - NCT06966050Recruiting
Blood test registry for inflammatory breast cancer
This study collects blood samples from people with inflammatory breast cancer (IBC) to learn more about the disease. It uses a special blood test called Signatera to look for cancer DNA, and the information is stored in a registry for research.
Houston, TexasAges 18 years+ - NCT06974786RecruitingPhase 2
T-cell engager vs stem cell transplant for newly diagnosed myeloma
This trial compares two approaches after initial therapy for newly diagnosed multiple myeloma: a T-cell engager (elranatamab) versus a stem cell transplant. The goal is to see which provides better control of the disease, using sensitive MRD testing to guide further treatment.
Birmingham, AlabamaAges 19 years+ - NCT06991868Recruiting
Urine test to monitor for urothelial cancer recurrence
This study uses a urine test to detect small amounts of cancer DNA (microscopic residual disease) after treatment, to see if it can catch a recurrence earlier than standard scans or cystoscopy. It includes four groups of people with different types and stages of urothelial cancer (in the kidney, ureter, or bladder) to see how well the test works for each group.
Beijing, Beijing MunicipalityAges 1.5 years+ - NCT06993675RecruitingPhase 2
T-cell therapy for MRD in newly diagnosed myeloma patients after transplant
This trial tests two drugs (talquetamab and teclistamab) to see if they can eliminate remaining cancer cells in newly diagnosed myeloma patients who have already had a stem cell transplant. It may be an option if you have minimal residual disease (MRD) and a good response to initial treatment.
New Haven, ConnecticutAges 18 years+ - NCT07003737Recruiting
Blinatumomab before stem cell transplant for high-risk B-ALL
This trial tests giving a drug called blinatumomab before a stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) that is in remission and has no detectable cancer cells. The goal is to see if this extra treatment helps prevent the leukemia from coming back after transplant.
Hangzhou, ZhejiangAges 18–65 - NCT07006012Recruiting
Study of RGL-305 for lymphoma with minimal residual disease
This trial tests if a new treatment called RGL-305 can help people with lymphoma who still have tiny amounts of cancer cells left after previous treatment. It is for those whose disease has responded to prior therapy but is not completely gone at the genetic level.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07052695RecruitingPhase 1/Phase 2
Mosunetuzumab for clearing CLL cells after other treatments
This study tests a drug called mosunetuzumab to see if it can clear remaining cancer cells (minimal residual disease) in people with CLL or SLL who have already had certain treatments. It may help those whose blood tests show very low levels of leftover disease after BTK inhibitor or BCL2 inhibitor therapy.
Boston, MassachusettsAges 18 years+ - NCT07104058Recruiting
FAPI PET scan to predict relapse in IgG4-RD
This study tests whether a special PET scan (FAPI PET/CT) can detect tiny signs of disease activity (MRD) in people with stable IgG4-RD, and whether it helps predict who might relapse.
Beijing, Beijing MunicipalityAges 18–75 - NCT07106736RecruitingPhase 2
CAR-T for newly diagnosed multiple myeloma without transplant
This trial is testing a new immunotherapy treatment using CAR-T cells for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The treatment aims to target and destroy myeloma cells that have BCMA and GPRC5D proteins on their surface.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07126782RecruitingEarly Phase 1
Gene-edited immune cells for AML after transplant
This trial tests a type of immune cell called gamma-delta T cells in people with acute myeloid leukemia who still have minimal residual disease after a stem cell transplant. The goal is to see if these cells can clear the remaining leukemia cells safely and effectively.
BeijingAges 18 years+
Hear when a new MRD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mrd?
- Yes. Clin2 currently lists 110 recruiting mrd studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mrd trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mrd trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.